<H1>Chapter DOI: 10.1208/aapsj070477<br/>Cited-By Count: 4</H1><table border="1" width="30%"><tr><td>Total References</td><td>28</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>27</td></tr><tr><td>BibStructured Count</td><td width="10%">11</td></tr><tr><td>BibUnstructured Count</td><td width="10%">17</td></tr><tr><td>DOI already available in SpringerLink</td><td>3</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>USP. About USP&#8212;an overview</span>. Available at: <span style='background:#FF3300'>www.usp.org/aboutUSP/.Accessed</span> October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2</td><td>BibBook</td><td>Board of Trustees, United States Pharmacopeial Convention.<Emphasis Type="Italic">United States Pharmacopeial Convention Quinquennial Meeting 2000 Proceedings</Emphasis>. Rockville, Maryland: United States Pharmacopeial Convention; 2000:400.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>USP</span>. <span style='background:#FFD9B3'>Biological and Biotechnological Drug Substances and Products Workbook; November 18&#8211;21, 2003; Crystal City, VA</span>. <span style='background:#66FF66'>2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibBook</td><td>World Health Organization.<Emphasis Type="Italic">Consultation on International Biological Standards for In Vitro Diagnostic Procedures, Blood Safety, and Clinical Technology</Emphasis>. Geneva, Switzerland: World Health Organization; 2000.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td>Federal Food, Drug, and Cosmetics Act, <i>21USC</i> &#167; 321(g).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibUnstructured</td><td>United States Public Health Service Act, <i>42USC</i> &#167; 262(i).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibBook</td><td>National Biological Standards Board.<Emphasis Type="Italic">Biological Standards Act</Emphasis>. London, UK: The Stationer&#8217;s Office; 1975.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibUnstructured</td><td>The<i>BioPharm</i> Lexicon. <i>BioPharm</i>. 2002;15(suppl).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Office of the Special Assistant for Gulf War Illnesses</span>. <span style='background:#FFD9B3'>Observations TABA&#8212;acronyms, abbreviations, and glossary</span>. GulfLINK Web site. Available at: <span style='background:#FF3300'>www.gulflink.osd.mil/va/va_taba.htm</span>. Accessed October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>The Pharmacopoeia of the United States of America</span>. Boston, MA: Fells and Lilly, <span style='background:#66FF66'>1820</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibChapter</td><td>WHO Expert Committee on Specifications for Pharmaceutical Preparations, ed. Annex 11: Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products. In:<Emphasis Type="Italic">Thirty-Fourth Report</Emphasis>. Geneva, Switzerland: World Health Organization; 1999.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Williams RL, Chen ML, Hauck WW. Equivalence approaches.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2002;72:229&#8211;237.</td><td><a href=http://dx.doi.org/10.1067/mcp.2002.126705>10.1067/mcp.2002.126705</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Food and Drug Administration Modernization Act of 1997</span>. <i>21USC</i> 301 &#167; 116.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>ICH.</span> International Conference on Harmonization Q5E guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process. Available at: <span style='background:#FF3300'>www.ich.org/cache/compo/276-254-1.html</span>. Accessed October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>FDA Center for Drug Evaluation</span> and Research and Center for Biologics Evaluation and Research. Guidance for industry: premarketing risk assessment. Available at: <span style='background:#FF3300'>www.fda.gov/cber/gdlns/premarkrisk.pdf</span>. Accessed October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>FDA Center for Drug Evaluation</span> and Research and Center for Biologics Evaluation and Research. Guidance for industry: development and use of risk-minimization action plans. Available at: <span style='background:#FF3300'>www.fda.gov/cber/gdlns/riskminim.pdf</span>. Accessed October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibUnstructured</td><td>Task Force on Risk Managment. Managing the risks from medical product use: creating a risk management framework. Available at: <span style='background:#FF3300'>http://www.fda.gov/oc/tfrm/riskmanagement.html</span>. Accessed October 10, 2005.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibBook</td><td>Committee for Proprietary Medicinal Products.<Emphasis Type="Italic">Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Quality Issues</Emphasis>. London, England: European Medicines Evaluation Agency; 2003.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.<Emphasis Type="Italic">J Pharmacokinet Biopharm</Emphasis>. 1987;15:657&#8211;680.</td><td><a href=http://dx.doi.org/10.1007/BF01068419>10.1007/BF01068419</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>FDA.</span> Guidance for industry: statistical approaches to estabilishing bioequivalence. Available at: <span style='background:#FF3300'>www.fda.gov/cder/guidance/3616fnl.htm</span>. Accessed October 10, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>USP Open Presentations of Violand B, Workman W, Hardy M, Mulkerrin M, Davis G, Mire-Sluis A, Cavagnaro J, Rogge M, Balthasar J, Swanson S, Hauck W.</span>, <span style='background:#FFD9B3'>Conference on Biological and Biotechnological Drug Substances and Products</span>. November 18&#8211;21, <span style='background:#66FF66'>2003</span>; <span style='background:#C0FFC0'>Arlington, VA</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Mire-Sluis AR, Das RG, Padilla A. WHO cytokine standardization: facilitating the development of cytokines in research, diagnosis, and as therapeutic agents.<Emphasis Type="Italic">J Immunol Methods</Emphasis>. 1998;216:103&#8211;116.</td><td><a href=http://dx.doi.org/10.1016/S0022-1759(98)00073-8>10.1016/S0022-1759(98)00073-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Mire-Sluis AR, Padilla A, Das RG. Biological standardization of cytokines and growth factors.<Emphasis Type="Italic">Dev Biol Stand</Emphasis>. 1999;97:171&#8211;176.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Hauck WW, Capen RC, Callahan JD, et al. Assessing parallelism prior to determining relative potency.<Emphasis Type="Italic">PDA J Pharm Sci Technol</Emphasis>. 2005;59:127&#8211;137.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibUnstructured</td><td>ICH. E10 guideline, Choice of control group in clinical trials. Available at: <span style='background:#FF3300'>www.ich.org/MediaServer.jser?@_ID=486&@_MODE=GLB</span>. Accessed October 11, 2005.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Copmann T, Davis G, Garnick R, et al. One product, one process, one set of specifications.<Emphasis Type="Italic">Pharm Technol</Emphasis>. 2001;25:26&#8211;36.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>ICH</span>. <span style='background:#FFD9B3'>Q6B Guideline, Specifications: test procedures and acceptance criteria for biotechnological/biological products</span>. Available at: <span style='background:#FF3300'>www.ich.org/MediaServer.jser?@_ID=432&@_MODE=GLB</span>. Accessed October 11, <span style='background:#66FF66'>2005</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28</td><td>BibUnstructured</td><td>Anon. Clearer paradigm sought for biopharmaceutical <i>specifications:Gold Sheet</i>. <span style='background:#66FF66'>2004</span>;<span style='background:#FFCC66'>38</span>:<span style='background:#D279FF'>1&#8211;32</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>